Subdural hematoma medical therapy: Difference between revisions

	Subdural Hematoma Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Subdural Hematoma from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X-ray
Echocardiography and Ultrasound
CT
MRI
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Subdural hematoma medical therapy On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Subdural hematoma medical therapy All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Subdural hematoma medical therapy
CDC on Subdural hematoma medical therapy
Subdural hematoma medical therapy in the news
Blogs on Subdural hematoma medical therapy
Directions to Hospitals Treating Subdural hematoma
Risk calculators and risk factors for Subdural hematoma medical therapy

← Older edit Newer edit →

VisualWikitext

Revision as of 12:40, 11 June 2019

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Fahimeh Shojaei, M.D.

Overview

Surgery is the mainstay of treatment for subdural hematoma. Pharmacologic medical therapies for subdural hematoma include corticosteroids, atorvastatin, tranexamic acid, etizolam, and ACE inhibitor.

Medical Therapy

Surgery is the mainstay of treatment for subdural hematoma.

Pharmacologic medical therapies for subdural hematoma include corticosteroids, atorvastatin, tranexamic acid, etizolam, and ACE inhibitor.^[1]
In patients with anticoagulation problem we have to correct the coagulation system:
- Prothrombin complex concentrate (PCC) for patients who use warfarin or other vitamin K antagonist (VKA)
- Idarucizumab for patients who use dabigatran
- Andexanet alfa for patients who use direct factor Xa inhibitor
- Protamine sulfate for patients who use heparin

References

↑ Thotakura, AmitKumar; Marabathina, NageswaraRao (2018). "The role of medical treatment in chronic subdural hematoma". Asian Journal of Neurosurgery. 13 (4): 976. doi:10.4103/ajns.AJNS_13_17. ISSN 1793-5482.

Template:WH Template:WS

[ThotakuraMarabathina2018-1] Thotakura, AmitKumar; Marabathina, NageswaraRao (2018). "The role of medical treatment in chronic subdural hematoma". Asian Journal of Neurosurgery. 13 (4): 976. doi:10.4103/ajns.AJNS_13_17. ISSN 1793-5482.

[1]

@@ Line 5: / Line 5: @@
 ==Overview==
-Pharmacologic medical therapies for [disease name] include corticosteroids, atorvastatin, tranexamic acid, etizolam, and ACE inhibitor.
+Surgery is the mainstay of treatment for subdural hematoma. Pharmacologic medical therapies for subdural hematoma include corticosteroids, atorvastatin, tranexamic acid, etizolam, and ACE inhibitor.
 ==Medical Therapy==
-*Pharmacologic medical therapies for [disease name] include corticosteroids, atorvastatin, tranexamic acid, etizolam, and ACE inhibitor.<ref name="ThotakuraMarabathina2018">{{cite journal|last1=Thotakura|first1=AmitKumar|last2=Marabathina|first2=NageswaraRao|title=The role of medical treatment in chronic subdural hematoma|journal=Asian Journal of Neurosurgery|volume=13|issue=4|year=2018|pages=976|issn=1793-5482|doi=10.4103/ajns.AJNS_13_17}}</ref>
+* Surgery is the mainstay of treatment for subdural hematoma.
+*Pharmacologic medical therapies for subdural hematoma include corticosteroids, atorvastatin, tranexamic acid, etizolam, and ACE inhibitor.<ref name="ThotakuraMarabathina2018">{{cite journal|last1=Thotakura|first1=AmitKumar|last2=Marabathina|first2=NageswaraRao|title=The role of medical treatment in chronic subdural hematoma|journal=Asian Journal of Neurosurgery|volume=13|issue=4|year=2018|pages=976|issn=1793-5482|doi=10.4103/ajns.AJNS_13_17}}</ref>
 *In patients with anticoagulation problem we have to correct the coagulation system:
 **Prothrombin complex concentrate (PCC) for patients who use warfarin or other vitamin K antagonist (VKA)
@@ Line 14: / Line 16: @@
 **Andexanet alfa for patients who use direct factor Xa inhibitor
 **Protamine sulfate for patients who use heparin
-===Disease Name===
-* '''1 Stage 1 - Name of stage'''
-** 1.1 '''Specific Organ system involved 1'''
-*** 1.1.1 '''Adult'''
-**** Preferred regimen (1): [[drug name]] 100 mg PO q12h for 10-21 days '''(Contraindications/specific instructions)'''
-**** Preferred regimen (2): [[drug name]] 500 mg PO q8h for 14-21 days
-**** Preferred regimen (3): [[drug name]] 500 mg q12h for 14-21 days
-**** Alternative regimen (1): [[drug name]] 500 mg PO q6h for 7–10 days
-**** Alternative regimen (2): [[drug name]] 500 mg PO q12h for 14–21 days
-**** Alternative regimen (3): [[drug name]] 500 mg PO q6h for 14–21 days
-*** 1.1.2 '''Pediatric'''
-**** 1.1.2.1 (Specific population e.g. '''children < 8 years of age''')
-***** Preferred regimen (1): [[drug name]] 50 mg/kg PO per day q8h (maximum, 500 mg per dose)
-***** Preferred regimen (2): [[drug name]] 30 mg/kg PO per day in 2 divided doses (maximum, 500 mg per dose)
-***** Alternative regimen (1): [[drug name]]10 mg/kg PO q6h (maximum, 500 mg per day)
-***** Alternative regimen (2): [[drug name]] 7.5 mg/kg PO q12h (maximum, 500 mg per dose)
-***** Alternative regimen (3): [[drug name]] 12.5 mg/kg PO q6h (maximum, 500 mg per dose)
-****
 ==References==
 {{Reflist|2}}

Subdural hematoma medical therapy: Difference between revisions

Revision as of 12:40, 11 June 2019

Overview

Medical Therapy

References

Navigation menu

Search